Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: A 12- and 24-month follow-up from the e-STAR database in Spain

Applied Health Economics and Health Policy

Volumn 6, Issue 1, 2008, Pages 41-53

  Olivares, José M ^a   Rodriguez Martinez, Alfonso ^b   Burón, José A ^c   Alonso Escolano, David ^c   Rodriguez Morales, Alexander ^c  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Cost effectiveness; Risperidone, therapeutic use; Schizophrenia, treatment

Indexed keywords

LONG ACTING DRUG; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SUBSTITUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RELAPSE; SCHIZOPHRENIA;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAMUSCULAR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; REGISTRIES; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SPAIN;

EID: 51849166120     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.2165/00148365-200806010-00004     Document Type: Article

References (44)

1. McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004; 2: 13
2. Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Pham Physician 2007; 75: 1821-9
3. Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull 2006; 32 Suppl. 1: S44-63
4. Bromet EJ, Fennig S. Epidemiology and natural history of schizophrenia. Biol Psychiatry 1999; 46: 871-81
5. Bromet EJ, Naz B, Fochtmann LJ, et al. Long-term diagnostic stability and outcome in recent first-episode cohort studies of schizophrenia. Schizophr Bull 2005; 31: 639-49
6. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes: II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 1991; 48: 978-86
7. Freedman R. Schizophrenia. N Engl J Med 2003; 349: 1738-49
8. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154 (4 Suppl.): 1-63
9. National Collaborating Centre for Mental Health and the National Institute for Clinical Excellence. Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care. London: Gaskell and the Royal College of Psychiatrists & the British Psychological Society, 2003 [online]. Available from URL: http://www.nice.org.uk/Guidance/CG1 [Accessed 2008 Feb 18]
10. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24: 1-10
11. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-22
12. Wang X, Savage R, Borisov A, et al. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. J Psychiatr Res 2006; 40: 669-76
13. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23
14. Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ 2007; 10: 23-41
15. Oliva-Moreno J. The costs of schizophrenia in Spain. Eur J Health Econ 2006; 7: 182-8
16. Lang HC, Su TP. The cost of schizophrenia treatment in Taiwan. Psychiatr Serv 2004; 55: 928-30
17. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005; 66: 1122-9
18. Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158: 1835-42
19. Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004; 184: 509-16
20. Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184: 346-51
21. Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin 2005; 21: 2017-28
22. Rémillard S, Pourcher E, Cohen H. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia. J Int Neuropsychol Soc 2008; 14: 110-8
23. Gaebel W, Riesbeck M, Wölwer W, et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2007; 68: 1763-74
24. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64: 1250-7
25. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125-32
26. Martin SD, Libretto SE, Pratt DJ, et al. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin 2003; 19: 298-305
27. Lindenmayer JP, Eerdekens E, Berry SA, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004; 65: 1084-9
28. Marinis TD, Saleem PT, Glue P, et al. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 2007; 40: 257-63
29. Niaz OS, Haddal PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 2007; 116: 36-46
30. Baca E, Bobes J, Cañas F, et al. Cost-effectiveness analysis of long-acting injectable risperidone v. olanzapine and v. fluphenazine decanoate in treating schizophrenia [in Spanish]. Rev ESp Econ Salud 2005; 4: 273-85
31. Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 2005; 23 Suppl. 1: 3-16
32. Heeg B, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005; 23 Suppl. 1: 17-33
33. Laux G, Heeg B, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005; 23 Suppl. 1: 49-61
34. Chue PS, Heeg B, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005; 23 Suppl. 1: 62-74
35. De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005; 23 Suppl. 1: 35-47
36. Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005; 23 Suppl. 1: 75-89
37. Annemans L. Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us? Pharmacoeconomics 2005; 23 Suppl. 1: 1-2
38. Sinaem prescribing information [online]. Available from URL: https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm [Accessed 2008 Feb 18]
39. Medicom SA. Vademecum internacional. Madrid: Medi Medic, 2005
40. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. Aliment Pharmacol Ther 2006; 23: 409-19
41. Parellada E. Clinical experience and management considerations with long-acting risperidone. Curr Med Res Opin. 2006 Feb; 22 (2): 241-55
42. Bounthavong M, Okamoto MP. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. J Eval Clin Pract 2007; 13: 453-60
43. Lorca PM, Miadi-Fargier H, Lançon C, et al. Cost-effectiveness analysis of schizophrenia patient care settings: impact of an atypical antipsychotic under long-acting injection [in French]. Encephale 2005; 31: 235-46
44. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK: a simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000; 17: 383-9